Barrett’s oESophagus trial 3 (BEST3): study protocol for a randomised controlled trial comparing the Cytosponge-TFF3 test with usual care to facilitate the diagnosis of oesophageal pre-cancer in primary care patients with chronic acid reflux

Table 4 Baseline and follow up data to be collected

Baseline data extract		12 month follow up extract
Time point/period	Variable	Time point/period	Variable
Baseline	Sex	Baseline	Sex
	Age	Baseline	Age
	Obesity records	Baseline and 12 months (where available)	Obesity records
	Smoking status		Smoking status
	Alcohol consumption		Alcohol consumption
Previous 12 months	PPI / H2RA prescriptions	Previous 12 months	PPI / H2RA prescriptions
	Other prescription medication: Aspirin, COX2i, antibiotics for H. pylori eradication		Other prescription medication: Aspirin, COX2i, antibiotics for H. Pylori eradication
	Heartburn and / or GERD related symptoms		Heartburn and / or GERD related symptoms
			Number of GP and practice nurse visits at home and at the practice
			Number of endoscopy or GI referrals
			Diagnosis of BE
			Diagnosis of EAC or pre-malignant conditions
			Diagnosis of benign oesophageal conditions
			Records on any upper GI specific procedures, e.g. endotherapies or oesophagectomies
			Anonymised endoscopy reports including pathology reports for BE and OC diagnosis; and benign conditions via a tick box (EoE, candida, inflammation, ulcer slough, squamous dysplasia, herpes, other)
			Type of referral: emergency via A&E, 2 week wait / urgent, routine and in or out patient (either form GP records or endoscopy report)
			Number of biopsies (from endoscopy reports)
			Anonymised letters from upper GI consultants

ISSN: 1471-2407